Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 75

Tissue-glue injection into the pancreas during pancreaticoduodenectomy

Official title: Efficacy of Pancreatic Parenchymal N-Butyl-2-Cyanoacrylate Injection in Pancreaticojejunostomy After Pancreaticoduodenectomy: A Randomized Controlled Trial

Run by Minia University · NCT07230509 · Data updated 2026-11-12

This trial will test whether injecting a tissue glue called N-butyl-2-cyanoacrylate into the pancreatic remnant during pancreaticoduodenectomy reduces postoperative pancreatic fistulas in patients with a soft pancreas and a small main duct.

More Pancreas Cancer trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment90 (estimated)
SponsorMinia University
Academic / other
Locations1 site (Minya, Minya Governorate)
StatusRecruiting
StartedDecember 1, 2025
Main results expectedDecember 1, 2027
Study endsDecember 20, 2027
Registry record updatedDecember 2, 2025
Trial IDNCT07230509 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients undergoing pancreaticoduodenectomy with curative intent for pancreatic or periampullary cancers who have a soft pancreas, a main pancreatic duct under 3 mm, and are medically fit to consent and undergo surgery.

Probably not a fit

Patients with a hard fibrotic pancreas, large ducts, active pancreatic remnant pancreatitis, distant metastases, vascular invasion requiring resection, or those unfit for surgery are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized controlled phase 2 trial that will enroll about 90 patients undergoing pancreaticoduodenectomy for malignant disease and randomly assign them to receive pancreatic parenchymal injection of N-butyl-2-cyanoacrylate (NBCA) or standard pancreaticojejunostomy alone. The primary outcome is the incidence of postoperative pancreatic fistula (POPF) using ISGPS definitions, with secondary outcomes including length of hospital stay, readmission, reoperation, mortality, and other postoperative complications. The intervention uses NBCA, a tissue adhesive with hemostatic and sealing properties, delivered into the pancreatic parenchyma during the anastomosis. The trial is single-center at Minia University and targets patients with soft pancreatic texture and a main duct diameter under 3 mm.

Why it matters

Potential benefit: If successful, this technique could lower rates of postoperative pancreatic fistula, shorten hospital stays, and reduce reoperations and other complications.

How similar studies have gone: NBCA and other tissue adhesives have been used successfully in various surgical settings and small case series suggest potential benefit for sealing pancreatic tissue, but randomized controlled evidence specifically in pancreaticoduodenectomy is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients undergoing pancreaticoduodenectomy for malignant lesions meeting the curative treatment intent in accordance with clinical guidelines.
* Soft pancreatic texture.
* Small main pancreatic duct diameter (\<3 mm).
* Informed consent obtained.

Exclusion Criteria:

* Known hypersensitivity to cyanoacrylate or Lipiodol®.
* Extremely hard, fibrotic pancreas.
* Significant pancreatitis involving the pancreatic remnant.
* Active infection at the surgical site.
* Uncontrolled coagulopathy.
* Unfit patients for surgery due to severe medical illness.
* Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.
* Irresectable tumors in diagnostic laparoscopy.
* Patients requiring left, central or total pancreatectomy or other palliative surgery.
* Pregnant or breastfeeding women.
* Patients with serious mental disorders.
* Patients with vascular invasion and requiring vascular resection.
* Patients refused to participate in the study.

Where it's running

  • Liver and GIT hospital , Minia University
    Minya, Minya Governorate, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.